Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Study Details
Study Description
Brief Summary
In view of the prolongation of patients living with HIV's life expectancy, the question of optimization of ART, which is still a life-long treatment, becomes central. While most patients achieve virological success, their treatments often need to be optimized in order to limit adverse events, drugs interactions and to improve adherence. The switch to dual regimen strategies represent one of the approaches for treatment optimization. Indeed, dual therapy regimens have shown non-inferior efficacy vs triple therapy as simplification therapy and more recently also as first line therapy. From the real-life data it emerges that today in simplification strategies, the dual regimen therapies are prescribed even in patients with a history of virological failure. Circulating HIV-1 resistant variants can be archived in viral reservoirs, where they can persist for years and can reemerge in case of therapeutic selective pressure. In particular, previous selection of M184V may have an impact on virological response to 3TC/DTG. There are few data on a direct comparison of 3TC/DTG efficacy in patients harboring or not harboring the M184V. So, there is a need to assess the efficacy of 3TC/DTG in patients with past M184V mutation in a large set of patients followed in clinical setting.
Thus, the investigators propose a retrospective study of patients with HIV-RNA ≤50 copies/mL who were switched to 3TC/DTG in order to compare the virological efficacy of 3TC/DTG in patients with and without a history of M184V detection in a previous resistance genotype. This study aimed to analyze 800 patients switched to DTG/3TC in clinical real setting in large European (France, Italy, Spain) database.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| M184V + group and M184 - group
|
Outcome Measures
Primary Outcome Measures
- probability of virological failure [12 months]
probability of virological failure that is defined as HIV-RNA >50 copies/mL in 2 consecutive determinations or ≥200 copies/mL in a single determination. This outcome will be evaluated overall and between the M184V- and M184V+ patients' groups.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
HIV-1 infected
-
Age ≥ 18 years
-
Switched to 3TC/DTG while having HIV-RNA ≤50 copies/mL on any ART regimen
-
Followed for at least 1 year after 3TC/DTG switch
-
With at least 1 previous genotype
-
With at least 1 virological follow-up after switching to 3TC/DTG
Exclusion Criteria:
- No genotypic resistance test available before switching to DTG/3TC
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | ARVD | Paris | France |
Sponsors and Collaborators
- Association de Recherche en Virologie et Dermatologie
Investigators
- Principal Investigator: Anne-Genevieve Marcelin, PharmD, PhD, Sorbonne University; APHP
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ARVD-LAMRES